JPWO2019149782A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019149782A5 JPWO2019149782A5 JP2020541689A JP2020541689A JPWO2019149782A5 JP WO2019149782 A5 JPWO2019149782 A5 JP WO2019149782A5 JP 2020541689 A JP2020541689 A JP 2020541689A JP 2020541689 A JP2020541689 A JP 2020541689A JP WO2019149782 A5 JPWO2019149782 A5 JP WO2019149782A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ttds
- amino acid
- palm
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 34
- 235000001014 amino acid Nutrition 0.000 claims 25
- 229940024606 amino acid Drugs 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 229920001223 polyethylene glycol Polymers 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 13
- 239000004475 Arginine Substances 0.000 claims 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 12
- 239000004472 Lysine Substances 0.000 claims 12
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 9
- 235000004279 alanine Nutrition 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 7
- 235000004554 glutamine Nutrition 0.000 claims 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 claims 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims 3
- 229960002173 citrulline Drugs 0.000 claims 3
- 235000013477 citrulline Nutrition 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- CPUSCHYXEUZMSV-UHFFFAOYSA-N 2,6-diamino-2-methylhexanoic acid Chemical compound OC(=O)C(N)(C)CCCCN CPUSCHYXEUZMSV-UHFFFAOYSA-N 0.000 claims 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 claims 2
- TUKKZLIDCNWKIN-VIFPVBQESA-N 5-chloro-L-tryptophan zwitterion Chemical compound C1=C(Cl)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 TUKKZLIDCNWKIN-VIFPVBQESA-N 0.000 claims 2
- INPQIVHQSQUEAJ-UHFFFAOYSA-N 5-fluorotryptophan Chemical compound C1=C(F)C=C2C(CC(N)C(O)=O)=CNC2=C1 INPQIVHQSQUEAJ-UHFFFAOYSA-N 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 125000003892 C18 acyl group Chemical group 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 2
- 229930195711 D-Serine Natural products 0.000 claims 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 101000869643 Homo sapiens Relaxin receptor 1 Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 208000004302 Microvascular Angina Diseases 0.000 claims 2
- 208000026018 Microvascular coronary artery disease Diseases 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 102100032444 Relaxin receptor 1 Human genes 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- HYOWVAAEQCNGLE-JTQLQIEISA-N alpha-methyl-L-phenylalanine Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-JTQLQIEISA-N 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 230000008085 renal dysfunction Effects 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims 1
- ZTTWHZHBPDYSQB-LBPRGKRZSA-N (2s)-2-amino-3-(1h-indol-3-yl)-2-methylpropanoic acid Chemical compound C1=CC=C2C(C[C@@](N)(C)C(O)=O)=CNC2=C1 ZTTWHZHBPDYSQB-LBPRGKRZSA-N 0.000 claims 1
- LKRMSSDDHQZQHJ-ZETCQYMHSA-N (2s)-2-amino-5-(diaminomethylideneamino)-2-methylpentanoic acid Chemical compound OC(=O)[C@](N)(C)CCCN=C(N)N LKRMSSDDHQZQHJ-ZETCQYMHSA-N 0.000 claims 1
- CDUUKBXTEOFITR-BYPYZUCNSA-N 2-methyl-L-serine Chemical compound OC[C@@]([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-BYPYZUCNSA-N 0.000 claims 1
- ARSWQPLPYROOBG-ZETCQYMHSA-N 2-methylleucine Chemical compound CC(C)C[C@](C)(N)C(O)=O ARSWQPLPYROOBG-ZETCQYMHSA-N 0.000 claims 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims 1
- KVNPSKDDJARYKK-JTQLQIEISA-N 5-methoxytryptophan Chemical compound COC1=CC=C2NC=C(C[C@H](N)C(O)=O)C2=C1 KVNPSKDDJARYKK-JTQLQIEISA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-N N-6-Trimethyllysine Chemical compound C[N+](C)(C)CCCC[C@H](N)C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- CDUUKBXTEOFITR-UHFFFAOYSA-N alpha-methylserine Natural products OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305094 | 2018-01-31 | ||
| EP18305094.7 | 2018-01-31 | ||
| PCT/EP2019/052298 WO2019149782A1 (en) | 2018-01-31 | 2019-01-30 | Modified lipidated relaxin b chain peptides and their therapeutic use |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512099A JP2021512099A (ja) | 2021-05-13 |
| JP2021512099A5 JP2021512099A5 (https=) | 2022-02-02 |
| JPWO2019149782A5 true JPWO2019149782A5 (https=) | 2022-02-02 |
| JP7295871B2 JP7295871B2 (ja) | 2023-06-21 |
Family
ID=61223862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541689A Active JP7295871B2 (ja) | 2018-01-31 | 2019-01-30 | 修飾された脂質化リラキシンｂ鎖ペプチドおよびその治療的使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10961295B2 (https=) |
| EP (1) | EP3746467B1 (https=) |
| JP (1) | JP7295871B2 (https=) |
| KR (1) | KR102755938B1 (https=) |
| CN (1) | CN111770934B (https=) |
| AR (1) | AR114325A1 (https=) |
| AU (1) | AU2019214358B2 (https=) |
| BR (1) | BR112020014834A2 (https=) |
| CA (1) | CA3089657A1 (https=) |
| CO (1) | CO2020008308A2 (https=) |
| DK (1) | DK3746467T3 (https=) |
| ES (1) | ES3058633T3 (https=) |
| FI (1) | FI3746467T3 (https=) |
| HR (1) | HRP20260016T1 (https=) |
| IL (2) | IL316406A (https=) |
| LT (1) | LT3746467T (https=) |
| MA (1) | MA52994A (https=) |
| MX (1) | MX2020008096A (https=) |
| MY (1) | MY199821A (https=) |
| NZ (1) | NZ766762A (https=) |
| PH (1) | PH12020551118A1 (https=) |
| PL (1) | PL3746467T3 (https=) |
| PT (1) | PT3746467T (https=) |
| RS (1) | RS67606B1 (https=) |
| SG (1) | SG11202006903WA (https=) |
| SI (1) | SI3746467T1 (https=) |
| TW (1) | TWI763972B (https=) |
| UY (1) | UY38069A (https=) |
| WO (1) | WO2019149782A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110637027B (zh) | 2017-02-08 | 2024-08-30 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| WO2019149781A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| MA52994A (fr) | 2018-01-31 | 2021-05-05 | Sanofi Sa | Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| US20240400638A1 (en) * | 2021-08-23 | 2024-12-05 | Guido MAGNI | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| WO2023086913A2 (en) | 2021-11-11 | 2023-05-19 | Tectonic Therapeutic, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| CN115998842B (zh) * | 2022-09-02 | 2025-08-26 | 郑州大学第一附属医院 | 一种逆转肝星形细胞激活的仿生纳米药物及其应用 |
| KR20260035823A (ko) | 2023-05-18 | 2026-03-13 | 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 | 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법 |
| KR20250054870A (ko) * | 2023-10-16 | 2025-04-24 | (주)케어젠 | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0923283A2 (pt) * | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| TW201315739A (zh) * | 2011-07-01 | 2013-04-16 | 拜耳智慧財產有限公司 | 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途 |
| EP2726502A1 (en) * | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
| JP6276690B2 (ja) * | 2011-08-04 | 2018-02-07 | ファリス バイオテック ゲーエムベーハー | ヒトリラキシン−２を調製する方法 |
| US20160152679A1 (en) | 2012-05-24 | 2016-06-02 | Angion Biomedica Corp. | Relaxin-like compounds and uses thereof |
| CN105792851B (zh) * | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| CA2945838C (en) * | 2014-04-17 | 2022-08-16 | The Florey Institute Of Neuroscience And Mental Health | Modified relaxin b chain peptides |
| EP3838285A1 (en) * | 2014-04-22 | 2021-06-23 | TXP Pharma GmbH | Peptide analogues with branched amino acid probe(s) |
| CN110637027B (zh) * | 2017-02-08 | 2024-08-30 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| MA52994A (fr) | 2018-01-31 | 2021-05-05 | Sanofi Sa | Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique |
| TW201934572A (zh) * | 2018-01-31 | 2019-09-01 | 法商賽諾菲公司 | 經修飾之鬆弛素ｂ鏈胜肽及其治療用途 |
| WO2019149781A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| US20240400638A1 (en) * | 2021-08-23 | 2024-12-05 | Guido MAGNI | Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions |
-
2019
- 2019-01-30 MA MA052994A patent/MA52994A/fr unknown
- 2019-01-30 WO PCT/EP2019/052298 patent/WO2019149782A1/en not_active Ceased
- 2019-01-30 ES ES19702593T patent/ES3058633T3/es active Active
- 2019-01-30 MX MX2020008096A patent/MX2020008096A/es unknown
- 2019-01-30 PL PL19702593.5T patent/PL3746467T3/pl unknown
- 2019-01-30 FI FIEP19702593.5T patent/FI3746467T3/fi active
- 2019-01-30 CN CN201980015588.9A patent/CN111770934B/zh active Active
- 2019-01-30 HR HRP20260016TT patent/HRP20260016T1/hr unknown
- 2019-01-30 JP JP2020541689A patent/JP7295871B2/ja active Active
- 2019-01-30 NZ NZ766762A patent/NZ766762A/en unknown
- 2019-01-30 AU AU2019214358A patent/AU2019214358B2/en active Active
- 2019-01-30 RS RS20260005A patent/RS67606B1/sr unknown
- 2019-01-30 LT LTEPPCT/EP2019/052298T patent/LT3746467T/lt unknown
- 2019-01-30 EP EP19702593.5A patent/EP3746467B1/en active Active
- 2019-01-30 SI SI201931009T patent/SI3746467T1/sl unknown
- 2019-01-30 SG SG11202006903WA patent/SG11202006903WA/en unknown
- 2019-01-30 PT PT197025935T patent/PT3746467T/pt unknown
- 2019-01-30 IL IL316406A patent/IL316406A/en unknown
- 2019-01-30 DK DK19702593.5T patent/DK3746467T3/da active
- 2019-01-30 MY MYPI2020003535A patent/MY199821A/en unknown
- 2019-01-30 BR BR112020014834-2A patent/BR112020014834A2/pt unknown
- 2019-01-30 KR KR1020207020681A patent/KR102755938B1/ko active Active
- 2019-01-30 CA CA3089657A patent/CA3089657A1/en active Pending
- 2019-01-30 IL IL276170A patent/IL276170B2/en unknown
- 2019-01-31 US US16/264,643 patent/US10961295B2/en active Active
- 2019-01-31 TW TW108103457A patent/TWI763972B/zh active
- 2019-01-31 AR ARP190100222A patent/AR114325A1/es unknown
- 2019-01-31 UY UY38069A patent/UY38069A/es not_active Application Discontinuation
-
2020
- 2020-07-06 CO CONC2020/0008308A patent/CO2020008308A2/es unknown
- 2020-07-22 PH PH12020551118A patent/PH12020551118A1/en unknown
- 2020-10-30 US US17/086,183 patent/US11725036B2/en active Active
-
2023
- 2023-06-26 US US18/341,320 patent/US20240218042A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512099A5 (https=) | ||
| FI3746467T3 (fi) | Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö | |
| JP7312215B2 (ja) | Ｇｉｐアゴニスト化合物及び方法 | |
| JPWO2019149782A5 (https=) | ||
| KR102310389B1 (ko) | Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법 | |
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| JP6685046B2 (ja) | 長時間作用型アドレノメデュリン誘導体 | |
| IL275188B1 (en) | Use of cyclic tripeptide to improve cellular energy metabolism | |
| WO2013102211A2 (en) | Stabilized antiviral fusion helices | |
| JP2016519106A5 (https=) | ||
| JPWO2018052002A1 (ja) | Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ １結合ペプチド | |
| JP2025172864A5 (https=) | ||
| CN1662551A (zh) | 前列腺素e2受体亚型ep4的拮抗肽 | |
| JP2024532403A (ja) | 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ | |
| IL299778A (en) | Therapeutic use of glucagon derivative or conjugate thereof for liver disease | |
| CN1041524C (zh) | 由ｃ－活性蛋白质片段衍生的寡肽及其药物组合物 | |
| JPWO2021066600A5 (https=) | ||
| JP2018507187A5 (https=) | ||
| JP2021533128A5 (https=) | ||
| JPWO2023028008A5 (https=) | ||
| JP7218906B2 (ja) | 血管機能の検出方法、高血圧症の進行段階を判定する方法、高血圧症の進行段階を判定するためのキット及び高血圧症の治療効果の予測方法 | |
| WO1992019644A1 (fr) | Peptide vasodilatateur | |
| JP2016516752A (ja) | アテローム性動脈硬化症の治療および予防のための環状ペプチドの使用 | |
| JP2015151386A (ja) | 新規生理活性ペプチド及びその用途 | |
| JPWO2020120979A5 (https=) |